MD ANDERSON CANCER CENTER and AbbVie formed a three-year collaboration to perform preclinical and clinical studies evaluating immuno-oncology therapies. AbbVie and MD Anderson will each assign two scientists to a joint scientific committee, which will decide on which projects to pursue. The collaboration will begin with projects driven by AbbVie Biotherapeutics. Future projects will draw...
In this week's episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher, and Sara Willa Ernst, reporter, go on a trip into the world of federal health policy surrounding psychedelic medicine.
